| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.2 | 0.0001 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.17 | 0.0008 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.098 | 0.06 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.098 | 0.08 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.093 | 0.09 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.094 | 0.1 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.077 | 0.2 |